Molecular and cellular characterization of drug resistant hamster cell lines with alterations in ribonucleotide reductase
- PMID: 3053467
- DOI: 10.1002/ijc.2910420522
Molecular and cellular characterization of drug resistant hamster cell lines with alterations in ribonucleotide reductase
Abstract
Ribonucleotide reductase consists of 2 protein components frequently called M1 and M2. Hydroxyurea specifically inhibits DNA synthesis by interacting with the M2 protein and destroying a unique tyrosyl-free radical. We have carried out a molecular and cellular characterization of 2 Chinese hamster ovary cell lines exhibiting either low (HN(R)-AT) or relatively high (H(R)-R2T) resistance to the cytotoxic effects of hydroxyurea. Both drug-resistant lines have an increased level of ribonucleotide reductase activity. EPR measurements for tyrosyl-free radical content and studies with M1-specific antibodies indicated that the elevation in enzyme activity was entirely due to an increase in the M2 component. Studies with M1 cDNA showed that both drug-resistant cell lines contained a wild-type level of M1 mRNA and a wild-type M1 gene copy number. Studies with M2 cDNA indicated that the 2 drug-resistant lines possessed elevated levels of M2 message that could explain the observed increase in M2 component. The elevation of M2 mRNA in the most resistant line, H(R)-R2T, was due to an increase in M2 gene copy number. The low resistant cell line, HN(R)-AT, exhibited a wild-type M2 gene copy number, indicating that the increase in M2 gene message occurred through a process other than gene amplification. Enzyme kinetic studies with partially purified preparations from both drug resistant lines showed reduced sensitivity to hydroxyurea and to the negative allosteric effector, dATP. In addition to hydroxyurea, H(R)-R2T cells were also resistant to several other drugs whose site of action is the M2 component. Furthermore, H(R)-R2T cells were not cross-resistant to colchicine or puromycin, suggesting that hydroxyurea-resistant cells do not share the multi-drug resistance phenotype, which is frequently associated with cross-resistance to these drugs.
Similar articles
-
Molecular mechanisms of drug resistance involving ribonucleotide reductase: hydroxyurea resistance in a series of clonally related mouse cell lines selected in the presence of increasing drug concentrations.Cancer Res. 1988 Apr 15;48(8):2029-35. Cancer Res. 1988. PMID: 2832057
-
Correlation between levels of ferritin and the iron-containing component of ribonucleotide reductase in hydroxyurea-sensitive, -resistant, and -revertant cell lines.Biochem Cell Biol. 1991 Sep;69(9):635-42. doi: 10.1139/o91-094. Biochem Cell Biol. 1991. PMID: 1793565
-
Altered expression of ribonucleotide reductase and role of M2 gene amplification in hydroxyurea-resistant hamster, mouse, rat, and human cell lines.Somat Cell Mol Genet. 1987 Mar;13(2):155-65. doi: 10.1007/BF01534695. Somat Cell Mol Genet. 1987. PMID: 3551113
-
Regulation and drug resistance mechanisms of mammalian ribonucleotide reductase, and the significance to DNA synthesis.Biochem Cell Biol. 1990 Dec;68(12):1364-71. doi: 10.1139/o90-199. Biochem Cell Biol. 1990. PMID: 2085432 Review.
-
Hydroxyurea-The Good, the Bad and the Ugly.Genes (Basel). 2021 Jul 19;12(7):1096. doi: 10.3390/genes12071096. Genes (Basel). 2021. PMID: 34356112 Free PMC article. Review.
Cited by
-
Lack of correlation between deoxyribonucleotide pool sizes, spontaneous mutation rates and malignant potential in Chinese hamster ovary cells.J Cancer Res Clin Oncol. 1989;115(5):429-34. doi: 10.1007/BF00393331. J Cancer Res Clin Oncol. 1989. PMID: 2808480 Free PMC article.
-
Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential.Clin Exp Metastasis. 1998 Jan;16(1):43-9. doi: 10.1023/a:1006559901771. Clin Exp Metastasis. 1998. PMID: 9502076
-
The in vivo toxicity of hydroxyurea depends on its direct target catalase.J Biol Chem. 2010 Jul 9;285(28):21411-5. doi: 10.1074/jbc.M110.103564. Epub 2010 May 7. J Biol Chem. 2010. PMID: 20452979 Free PMC article.
-
A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study.Leuk Lymphoma. 2016 Oct;57(10):2307-14. doi: 10.3109/10428194.2016.1146947. Epub 2016 Feb 19. Leuk Lymphoma. 2016. PMID: 26895565 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources